Andrea Zaliani

Merck (Germany) — Germany

Computer Science · Physical Sciences

24h-index3.7kcitations169works2.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Computational Drug Discovery Methods(71), SARS-CoV-2 and COVID-19 Research(43), COVID-19 Clinical Research Studies(9), Bioinformatics and Genomic Networks(9), Cell Image Analysis Techniques(9)

Publications168 total

Cortical organoid-derived models of the melanoma brain metastatic niche enable prioritization of cancer-targeting drugs
Cell Reports Methods·2025· 1 citedOpen Access
Interdisciplinary Study on Drug-Induced-Phospholipidosis of Repurposing Libraries through Machine Learning and Experimental Evaluation in Different Cell Lines
2025
Morphological cell profiling for drug repurposing against SARS-CoV-2 infection
2025Open Access
Morphological profiling reveals neuroprotection via mitochondrial uncoupling in human dopaminergic neurons
Scientific Reports·2025Open Access
From Library to Landscape: Integrative Annotation Workflows for Compound Libraries in Drug Repurposing
2025Open Access
The fast‐dissociating D <sub>2</sub> antagonist antipsychotic JNJ‐37822681 is a neuronal Kv7 channel opener: Potential repurposing for epilepsy treatment
British Journal of Pharmacology·2025· 3 citedOpen Access
Optimization and Evaluation of Complementary Degrader Discovery Assays for Application in Screening
ACS Pharmacology & Translational Science·2025Open Access
Interdisciplinary Study on Drug-Induced-Phospholipidosis of Repurposing Libraries through Machine Learning and Experimental Evaluation in Different Cell Lines
2025Open Access
KGG: a fully automated workflow for creating disease-specific knowledge graphs
Bioinformatics·2025· 1 citedOpen Access
Pluripotent stem cell-based drug discovery uncovers sildenafil as a treatment for mitochondrial disease
2025· 4 citedOpen Access
Identification, validation, and characterization of approved and investigational drugs interfering with the <scp>SARS</scp>‐<scp>CoV</scp>‐2 endoribonuclease Nsp15
Protein Science·2025Open Access
Optimization and evaluation of complementary degrader discovery assays for application in screening
2025Open Access
Predicting Antimicrobial Class Specificity of Small Molecules Using Machine Learning
Journal of Chemical Information and Modeling·2025· 6 citedOpen Access
From library to landscape: integrative annotation workflows for compound libraries in drug repurposing
Database·2025· 2 citedOpen Access
Interdisciplinary Study on Drug-Induced-Phospholipidosis of Repurposing Libraries Through Machine Learning and Experimental Evaluation in Different Cell Lines
SSRN Electronic Journal·2025Open Access
Artificial intelligence-driven patent analysis in drug discovery
Elsevier eBooks·2025
Predicting antimicrobial class specificity of small molecules using machine learning
2024Open Access
Identification and development of TRPM4 antagonists to counteract neuronal excitotoxicity
iScience·2024· 3 citedOpen Access
Pharmacological profiles of neglected tropical disease drugs
Artificial Intelligence in the Life Sciences·2024· 1 citedOpen Access
Thiol-Reactive or Redox-Active: Revising a Repurposing Screen Led to a New Invalidation Pipeline and Identified a True Noncovalent Inhibitor Against Papain-like Protease from SARS-CoV-2
ACS Pharmacology & Translational Science·2024Open Access
page 1 of 9Next →

Frequent Co-authors

Philip Gribbon(24), Maria Kuzikov(14), Yojana Gadiya(9), Bernhard Ellinger(8), Carsten Claussen(8), Jeanette Reinshagen(8), Andrea R. Beccari(7), Paolo Mascagni(6), Markus Wolf(6), Gerd Geißlinger(6), Francesca Esposito(6), Enzo Tramontano(6), Elisa Costanzi(5), Angela Corona(5), Candida Manelfi(5), Paola Storici(5), Martin Hofmann‐Apitius(5), Matthias Rarey(4), Daniela Iaconis(4), Giulia Rossetti(4)